Lysosomal disease with epilepsy

Lysosomal disease with epilepsy (Orphanet code 225681) is a grouping category within the Orphanet classification system that encompasses a set of rare lysosomal storage disorders in which epilepsy (seizures) is a prominent clinical feature. Lysosomal storage disorders are caused by deficiencies in specific lysosomal enzymes or transport proteins, leading to the accumulation of undegraded substrates within lysosomes. This progressive accumulation damages cells throughout the body, with the central nervous system being particularly vulnerable. Diseases within this group include conditions such as the neuronal ceroid lipofuscinoses (CLN diseases), certain forms of gangliosidoses, sialidosis, and other lysosomal disorders where seizures — often progressive myoclonic epilepsy — are a defining feature. The neurological involvement in these conditions typically manifests as progressive cognitive decline, motor deterioration, visual impairment, and various seizure types including myoclonic, tonic-clonic, and absence seizures. Seizures may be refractory to standard antiepileptic medications and tend to worsen over time as substrate accumulation increases. Other body systems that may be affected include the visual system (retinal degeneration, cherry-red spot), the musculoskeletal system, and in some cases visceral organs such as the liver and spleen. Treatment for lysosomal diseases with epilepsy is largely supportive and symptomatic. Antiepileptic drugs are used to manage seizures, though response is often limited. For some underlying lysosomal disorders, disease-specific therapies such as enzyme replacement therapy, substrate reduction therapy, or hematopoietic stem cell transplantation may be available, though their effectiveness in controlling neurological manifestations including epilepsy varies. Gene therapy approaches are under active investigation for several of these conditions. Early diagnosis and multidisciplinary care involving neurologists, geneticists, and rehabilitation specialists are essential for optimizing quality of life.

Inheritance

Variable

Can be inherited in different ways depending on the underlying gene

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Source: openFDA + DailyMed · NDA / BLA labels with structured indications · refreshed weekly

Source: ClinicalTrials.gov · synced daily · phases, status, and PI names normalized at ingest

Source: NPI Registry + PubMed · trial PI roles cross-referenced with ClinicalTrials.gov · ranked by match score (publications + PI activity + community signal)

Source: NORD Rare Disease Centers + NIH Undiagnosed Diseases Network (UDN) · centers verified active within last 12 months

Source: PubMed + NIH RePORTER + openFDA + clinical-journal RSS · last 30 days · disease-tagged at ingest by AI extraction with human QC

Common questions about Lysosomal disease with epilepsy